Neuroimaging in Psychiatric Disorders
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
SummaryIn psychiatry, neuroimaging facilitates the diagnosis of psychiatric disorders and the development of new medications. It is used to detect structural lesions causing psychosis and to differentiate depression from neurodegenerative disorders or brain tumors. Functional neuroimaging, mostly in the form of molecular neuroimaging with positron emission tomography or single photon emission tomography, facilitates the identification of therapeutic targets, the determination of the dose of a new drug needed to occupy its target in the brain, and the selection of patients for clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whitfield-Gabrieli, S., Thermenos, H. W., Milanovic, S., Tsuang, M. T., Faraone, S. V., McCarley, R. W., Shenton, M. E., Green, A. I., Nieto-Castanon, A., LaViolette, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809141106 · Cited by 1,435 · cited 1×
“Decreased suppression of the restingstate brain network during stimulation paradigms has also been reported in schizophrenia [27].”
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 1×
“A D2 receptor marker ([(123)I]IBZM) is also commercially available in Europe and has been used in the USA for clinical studies of schizophrenia [43, 44].”
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · cited 2×
“This reduced binding may be explained by a greater receptor saturation or even by downregulation of the receptor, induced by an increased secretion of DA in these regions, and has also been documented in schizophrenia by means of [(18)F]fluoroDOPA PET [37].”
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608 · cited 1×
“1) [11].”
Meyer-Lindenberg, A. S., Olsen, R. K., Kohn, P. D., Brown, T., Egan, M. F., Weinberger, D. R., & Berman, K. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.379 · Cited by 574
Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues
Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., & Goodwin, G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.015 · Cited by 450
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328 · cited 1×
“However, network abnormalities may differ among individuals with the same diagnosis [19].”
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286 · cited 1×
“[52] Panel C is modified fromWong et al.”
Cited by
Phillips, C. (2017) · Neural Plasticity · doi:10.1155/2017/7260130 · Cited by 450
Gray, J. P., Müller, V. I., Eickhoff, S. B., & Fox, P. T. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19050560 · Cited by 449
“Neuroimaging approaches comprise a powerful, noninvasive method to investigate the neurobiological mechanisms underpinning psychiatric disorders (3, 4).”
Method(2021) · Research Design in Clinical Psychology · doi:10.1017/9781108993647.010 · Cited by 276
Research Design in Clinical Psychology
Kazdin, A. E. (2021) · doi:10.1017/9781108993647 · Cited by 240
Lu, Y.-C., Andescavage, N., Wu, Y., Kapse, K., Andersen, N. R., Quistorff, J., Saeed, H., Lopez, C., Henderson, D., Barnett, S. D., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00111-w · Cited by 46
Metadata
- Authors
- Masdeu, J. C.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 8
- Issue
- 1
- Pages
- 93-102
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W1965761694
- Cited by
- 101
- References
- 13
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroimaging in Psychiatric Disorders. https://app.cochat.ai/papers/10.1007/s13311-010-0006-0
- The paper
- Masdeu, J. C. (2011). Neuroimaging in Psychiatric Disorders. Neurotherapeutics. https://doi.org/10.1007/s13311-010-0006-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.